Iomai news from FiercePharma
News
ALSO NOTED: Abbott's Xience shows well against Boston Sci stent;AstraZeneca nabs new indication for Seroquel
> Abbott Laboratories' waiting-in-the-U.S.-wings stent, Xience, is as safe as and perhaps more effective than the current market leader made by Boston Scientific, according to new data presented Read more...
Iomai - Worst Pharma Stocks of 2007
Company: Iomai Starting stock price: $4.85 Ending stock price: $1.03 Percent Change: -78.76% Details: Iomai reported in May that it's needle-free flu vaccine Read more...
Get more Iomai coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets